Hyperkalemia Causes and Risk Factors

Primary Mechanisms

• Hyperkalemia results from three fundamental mechanisms: decreased renal potassium excretion, transcellular shift of potassium out of cells, or excessive potassium intake—with impaired renal excretion being the dominant cause in clinical practice 1

Decreased Renal Potassium Excretion

• The incidence of hyperkalemia increases dramatically with severity of renal impairment, occurring in up to 73% of patients with advanced chronic kidney disease (CKD) 1, 2
• Acute kidney injury is often accompanied by acute pancreatitis or hepatic failure, and was present in all cases of hyperkalemia-induced cardiac arrest in one retrospective analysis 3

Transcellular Potassium Shift

• Metabolic acidosis causes potassium to shift out of cells in exchange for hydrogen ions 1
• Massive tissue breakdown, such as rhabdomyolysis, tumor lysis syndrome, and severe burns, releases large amounts of intracellular potassium 3
• Hemolysis can occur in the body (true hyperkalemia) or in the test tube (pseudohyperkalemia) 2

Excessive Potassium Intake

• Potassium supplements are a direct exogenous source of potassium 2
• Salt substitutes often contain potassium chloride (e.g., DASH diet products) 2
• High-potassium foods, such as bananas, melons, orange juice, potatoes, and tomatoes, can contribute to hyperkalemia 2, 3

Drug-Induced Hyperkalemia

• Medications, particularly RAAS inhibitors, represent the most important iatrogenic cause of hyperkalemia in everyday clinical practice, with up to 40% of heart failure patients and 5-10% of combination therapy patients developing hyperkalemia 2, 3
• Potassium-sparing diuretics, such as spironolactone, triamterene, and amiloride, can cause hyperkalemia 2
• NSAIDs impair renal potassium excretion by reducing prostaglandin synthesis 2, 3

High-Risk Comorbidities

• Certain patient populations, such as those with advanced CKD, heart failure, diabetes mellitus, and advanced age, have dramatically elevated risk of developing hyperkalemia 1, 2, 4
• The risk of hyperkalemia increases proportionally with declining eGFR in patients with CKD 1, 2

Pseudohyperkalemia

• Pseudohyperkalemia represents falsely elevated potassium in the test tube without true elevation in the body, and can be caused by hemolysis during blood draw, prolonged tourniquet application, fist clenching during phlebotomy, or thrombocytosis or leukocytosis 2, 3
• If pseudohyperkalemia is suspected, repeat measurement with proper blood sampling technique or obtain an arterial sample for confirmation 2, 3

Critical Clinical Context

• The prevalence of hyperkalemia varies dramatically by setting, with 2-4% in the general population, 10-55% in hospitalized patients, and up to 73% in advanced CKD 2
• Both the absolute potassium level and the rate of rise determine clinical significance, with rapid increases more likely to cause cardiac abnormalities than gradual elevations over months 1

Hyperkalemia Risk Factors and Mechanisms

Patient Populations at High Risk

• The American College of Cardiology and other guideline societies acknowledge that patients with advanced CKD, heart failure, diabetes mellitus, resistant hypertension, myocardial infarction, and advanced age have a dramatically elevated risk of hyperkalemia 5
• Men have slightly higher risk than women after RAAS inhibitor initiation, according to the Mayo Clinic Proceedings 5

Mechanisms of Hyperkalemia

• Risk of hyperkalemia progressively increases as eGFR decreases, particularly when eGFR falls below 60 mL/min per 1.73 m² in patients on RAAS inhibitors, as reported in the Mayo Clinic Proceedings 5
• Hyperkalemia risk is generally increased once eGFR is less than 15 mL/min per 1.73 m², according to the Mayo Clinic Proceedings 5
• Trimethoprim and pentamidine can block epithelial sodium channels in the collecting duct, leading to hyperkalemia, as noted in the Mayo Clinic Proceedings 5
• Heparin and derivatives can suppress aldosterone synthesis, contributing to hyperkalemia, as reported in the Mayo Clinic Proceedings 5
• Insulin deficiency can impair cellular potassium uptake via Na/K-ATPase, according to the Mayo Clinic Proceedings 5

Diagnostic Considerations

• Pseudohyperkalemia can occur due to hemolysis during blood draw, prolonged tourniquet application, or delayed specimen processing, as described in the Mayo Clinic Proceedings 6
• Plasma potassium concentrations are usually 0.1-0.4 mEq/L lower than serum levels due to platelet potassium release during coagulation, as noted in the Mayo Clinic Proceedings 6
• If pseudohyperkalemia is suspected, repeat measurement with proper blood sampling technique or obtain an arterial sample for confirmation, as recommended in the Mayo Clinic Proceedings 6

Multiple Mechanisms

• Multiple mechanisms of hyperkalemia often coexist, such as CKD + RAAS inhibitor + NSAID, as reported in the Mayo Clinic Proceedings 5

Hyperkalemia Causes and Risk Factors

Medication-Induced Causes

• The American Heart Association recommends that beta-blockers can impair cellular potassium uptake, increasing the risk of hyperkalemia in patients with normal kidney function 7

High-Risk Comorbidities

• The American Diabetes Association notes that diabetes mellitus increases the risk of hyperkalemia through hyporeninemic hypoaldosteronism and insulin deficiency, even in patients with normal kidney function 7
• The American Geriatrics Society suggests that advanced age is associated with altered potassium homeostasis, increasing the risk of hyperkalemia in patients with normal kidney function 7

Risk Factors and Mechanisms Contributing to Hyperkalemia

Decreased Renal Potassium Excretion

• Hyperkalemia risk rises markedly when estimated glomerular filtration rate (eGFR) falls below 15 mL/min/1.73 m², reflecting severe impairment of renal potassium clearance. 8

Drug‑Induced Hyperkalemia (Iatrogenic Causes)

• Angiotensin‑converting‑enzyme inhibitors, angiotensin‑receptor blockers, and mineralocorticoid‑receptor antagonists lower aldosterone activity, thereby reducing renal potassium excretion. 8
• In patients receiving any renin‑angiotensin‑aldosterone system (RAAS) inhibitor, hyperkalemia risk is already elevated when eGFR < 60 mL/min/1.73 m² and increases progressively as renal function declines further. 8
• Trimethoprim and pentamidine inhibit epithelial sodium channels in the collecting duct, leading to impaired potassium secretion and hyperkalemia. 8
• Heparin and its derivatives suppress aldosterone synthesis, predisposing to hyperkalemia. 8
• Beta‑blockers diminish renin release and blunt cellular potassium uptake, contributing to elevated serum potassium. 8
• Calcineurin inhibitors (e.g., cyclosporine, tacrolimus) impair renal potassium excretion, increasing hyperkalemia risk. 8

Transcellular Potassium Shift

• Insulin deficiency hampers Na⁺/K⁺‑ATPase‑mediated cellular potassium uptake, causing a transient rise in extracellular potassium concentration. 8

High‑Risk Patient Populations

• Advanced chronic kidney disease (CKD) is strongly associated with hyperkalemia. 8
• Patients with heart failure have a markedly increased likelihood of developing hyperkalemia. 8
• Diabetes mellitus confers heightened hyperkalemia risk, even when renal function is relatively preserved. 8
• Resistant hypertension is linked to a greater incidence of hyperkalemia. 8
• Recent myocardial infarction is a recognized risk factor for hyperkalemia. 8
• Advanced age, reflecting age‑related alterations in potassium homeostasis, raises hyperkalemia susceptibility. 8

Hyperkalemia Incidence and Recurrence with RAAS‑Inhibitor Therapy

Incidence of Hyperkalemia with RAAS‑Inhibitor Use

• In hypertensive patients without additional risk factors, monotherapy with a RAAS inhibitor leads to hyperkalemia in < 2% of cases; the incidence rises to ≈ 5% with dual RAAS inhibition and to 5–10% when dual therapy is given to patients with heart failure or chronic kidney disease. 9

Mineralocorticoid Receptor Antagonist (MRA)‑Related Hyperkalemia

• Among NYHA Class II–IV heart‑failure patients who start an MRA, up to one‑third develop hyperkalemia (serum potassium > 5.0 mmol/L) within two years of therapy. 9

Real‑World Hyperkalemia Rates in Unselected Populations

• In routine clinical practice, hyperkalemia occurs in as many as 50% of patients receiving any RAAS‑inhibitor therapy, reflecting a high real‑world burden. 9

Recurrence of Hyperkalemia in Cardiovascular Disease + CKD

• Patients who have both cardiovascular disease and chronic kidney disease experience frequent hyperkalemia episodes, with 50% suffering two or more recurrences within a single year. 9